3 stories mentioning HKG:1099Updated 38d ago
Every FINWIRES story that references HKG:1099, newest first.
Sinopharm Group (HKG:1099) booked 1.41 billion yuan in attributable profit for the first quarter of 2026, falling from 1.46 billion yuan in the year-ago period, according to a Hong Kong bourse filing Monday.Earnings per share were 0.45 yuan, compared with 0.47 yuan in the prior year.Total operating revenue fell to 140.77 billion yuan from 141.66 billion yuan, figures showed.
Sinopharm (HKG:1099) unit China National Medical Device recorded an operating profit of 220.2 million yuan in the first quarter of 2026, down 20% from 276.7 million yuan a year prior, according to a Thursday Hong Kong bourse filing.Revenue jumped 1.2% to 17 billion yuan from 16.8 billion yuan in the prior-year period.
China National Accord Medicines' (SHE:000028, SHE:200028) attributable profit fell 12% in the three months ended March 31 to 287.5 million yuan from 328 million yuan a year prior, according to a Tuesday Hong Kong bourse filing by parent Sinopharm (HKG:1099).The drug company's basic EPS slid to 0.52 yuan from 0.59 yuan in the year-ago period.Revenue inched down 2.6% year over year to 17.8 billion yuan from 18.3 billion yuan previously.
